{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:17:02Z","timestamp":1791515822047,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004416","name":"Vlaamse Liga Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004416","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wetenschappelijk Fonds Willy Gepts"},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SRP-VUB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are among the most aggressive B cell non-Hodgkin lymphomas. Maternal embryonic leucine zipper kinase (MELK) plays a role in cancer cell cycle progression and is associated with poor prognosis in several cancer cell types. In this study, the role of MELK in DLBCL and MCL and the therapeutic potential of MELK targeting is evaluated. MELK is highly expressed in DLBCL and MCL patient samples, correlating with a worse clinical outcome in DLBCL. Targeting MELK, using the small molecule OTSSP167, impaired cell growth and survival and induced caspase-mediated apoptosis in the lymphoma cells. Western blot analysis revealed that MELK targeting decreased the phosphorylation of FOXM1 and the protein levels of EZH2 and several mitotic regulators, such as Cdc25B, cyclin B1, Plk-1, and Aurora kinases. In addition, OTSSP167 also sensitized the lymphoma cells to the clinically relevant Bcl-2 inhibitor venetoclax by strongly reducing Mcl1 levels. Finally, OTSSP167 treatment of A20-inoculated mice resulted in a significant prolonged survival. In conclusion, targeting MELK with OTSSP167 induced strong anti-lymphoma activity both in vitro and in vivo. These findings suggest that MELK could be a potential new target in these aggressive B cell malignancies.<\/jats:p>","DOI":"10.1038\/s41408-019-0249-x","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T18:02:07Z","timestamp":1574100127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma"],"prefix":"10.1038","volume":"9","author":[{"given":"Anke","family":"Maes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-2790","authenticated-orcid":false,"given":"Ken","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Vlummens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"De Raeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Devin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Szablewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"De Veirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-6581","authenticated-orcid":false,"given":"Eline","family":"Menu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5717-3207","authenticated-orcid":false,"given":"Jerome","family":"Moreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4012-4617","authenticated-orcid":false,"given":"Elke","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,18]]},"reference":[{"key":"249_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/2040620717719616","volume":"8","author":"B Fakhri","year":"2017","unstructured":"Fakhri, B. & Hahl, B. Current and emerging treatment options for mantle cell lymphoma. Ther. Adv. Hematol. 8, 223\u2013234 (2017).","journal-title":"Ther. Adv. Hematol."},{"key":"249_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3960\/jslrt.56.79","volume":"56","author":"K Miyazaki","year":"2016","unstructured":"Miyazaki, K. Treatment of diffuse large B-cell lymphoma. J. Clin. Exp. Hematop. 56, 79\u201388 (2016).","journal-title":"J. Clin. Exp. Hematop."},{"issue":"Suppl 1","key":"249_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hon.2581","volume":"37","author":"A Davies","year":"2019","unstructured":"Davies, A. Double-hit lymphoma: so what? Hematol Oncol. 37(Suppl 1), 19\u201323 (2019).","journal-title":"Hematol Oncol."},{"key":"249_CR4","doi-asserted-by":"publisher","first-page":"s125","DOI":"10.7861\/clinmedicine.16-6-s125","volume":"16","author":"T Cummin","year":"2016","unstructured":"Cummin, T. & Johnson, P. Lymphoma: turning biology into cures. Clin Med. 16, s125\u2013s129 (2016).","journal-title":"Clin Med."},{"key":"249_CR5","first-page":"2540","volume":"41","author":"L Ren","year":"2019","unstructured":"Ren, L., Deng, B., Saloura, V., Park, J. & Nakamura, Y. MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells. Oncol. Rep. 41, 2540\u20132548 (2019).","journal-title":"Oncol. Rep."},{"key":"249_CR6","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1038\/s41388-018-0333-x","volume":"37","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia. Oncogene. 37, 5520\u20135533 (2018).","journal-title":"Oncogene."},{"key":"249_CR7","doi-asserted-by":"crossref","unstructured":"Ganguly, R. et al. MELK\u2014a conserved kinase: functions, signaling, cancer, and controversy. Clin Transl Med. 4, 11 (2015).","DOI":"10.1186\/s40169-014-0045-y"},{"key":"249_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153518","volume":"11","author":"W Ji","year":"2016","unstructured":"Ji, W. et al. OTSSP167 abrogates mitotic checkpoint through inhibiting multiple mitotic kinases. PLoS ONE 11, e0153518 (2016).","journal-title":"PLoS ONE"},{"key":"249_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/stem.1358","volume":"31","author":"K Joshi","year":"2013","unstructured":"Joshi, K. et al. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 31, 1051\u20131063 (2013).","journal-title":"Stem Cells"},{"key":"249_CR10","doi-asserted-by":"publisher","first-page":"7630","DOI":"10.1038\/sj.onc.1205870","volume":"21","author":"N Davezac","year":"2002","unstructured":"Davezac, N., Baldin, V., Blot, J., Ducommun, B. & Tassan, J. Human pEg3 kinase associates with and phosphorylates CDC25B phosphatase: a potential role of pEg3 in cell cycle regulation. Oncogene. 21, 7630\u20137641 (2002).","journal-title":"Oncogene."},{"key":"249_CR11","doi-asserted-by":"publisher","first-page":"9751","DOI":"10.1158\/0008-5472.CAN-04-4531","volume":"65","author":"D Gray","year":"2005","unstructured":"Gray, D. et al. Maternal embryonic leucine zipper kinase\/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res. 65, 9751\u20139761 (2005).","journal-title":"Cancer Res."},{"key":"249_CR12","doi-asserted-by":"publisher","first-page":"21551","DOI":"10.3390\/ijms141121551","volume":"14","author":"P Jiang","year":"2013","unstructured":"Jiang, P. & Zhang, D. Maternal embryonic leucine zipper kinase (MELK): a novel regulator in cell cycle control, embryonic development, and cancer. Int. J. Mol. Sci. 14, 21551\u201321560 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"249_CR13","doi-asserted-by":"crossref","first-page":"18171","DOI":"10.18632\/oncotarget.7685","volume":"7","author":"S Chung","year":"2016","unstructured":"Chung, S. et al. Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor. Oncotarget. 7, 18171\u201318182 (2016).","journal-title":"Oncotarget."},{"key":"249_CR14","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.1002\/cam4.1816","volume":"7","author":"J Wang","year":"2018","unstructured":"Wang, J. et al. Maternal embryonic leucine zipper kinase: a novel biomarker and a potential therapeutic target of cervical cancer. Cancer Med. 7, 5665\u20135678 (2018).","journal-title":"Cancer Med."},{"key":"249_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1535-7163.MCT-18-0819","volume":"18","author":"A Chlenski","year":"2019","unstructured":"Chlenski, A. et al. Maternal embryonic leucine zipper kinase (MELK), A Potential Therapeutic Target for Neuroblastoma. Mol Cancer Ther. 18, 507\u2013516 (2019).","journal-title":"Mol Cancer Ther."},{"key":"249_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00109-012-0949-1","volume":"91","author":"R Kuner","year":"2013","unstructured":"Kuner, R. et al. The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J. Mol. Med. 91, 237\u2013248 (2013).","journal-title":"J. Mol. Med."},{"key":"249_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2350","volume":"11","author":"M Pickard","year":"2009","unstructured":"Pickard, M. et al. Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res. 11, R60 (2009).","journal-title":"Breast Cancer Res."},{"key":"249_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3324\/haematol.2017.172973","volume":"103","author":"A Bolomsky","year":"2018","unstructured":"Bolomsky, A. et al. Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma. Haematologica. 103, 325\u2013335 (2018).","journal-title":"Haematologica."},{"key":"249_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/ijc.23189","volume":"122","author":"S Marie","year":"2008","unstructured":"Marie, S. et al. Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int. J. Cancer. 122, 807\u2013815 (2008).","journal-title":"Int. J. Cancer."},{"key":"249_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bbrc.2011.07.060","volume":"412","author":"S Choi","year":"2011","unstructured":"Choi, S. & Ku, J. Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression. Biochem. Biophys. Res. Commun. 412, 207\u2013213 (2011).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"249_CR21","doi-asserted-by":"publisher","first-page":"12371","DOI":"10.18632\/oncotarget.2642","volume":"5","author":"H Alachkar","year":"2014","unstructured":"Alachkar, H. et al. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. Oncotarget. 5, 12371\u201312382 (2014).","journal-title":"Oncotarget."},{"key":"249_CR22","doi-asserted-by":"crossref","first-page":"13621","DOI":"10.18632\/oncotarget.7297","volume":"7","author":"H Inoue","year":"2016","unstructured":"Inoue, H. et al. Effective growth-suppressive activity of maternal embryonic leucin-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. 7, 13621\u201313633 (2016).","journal-title":"Oncotarget."},{"key":"249_CR23","doi-asserted-by":"crossref","first-page":"17652","DOI":"10.18632\/oncotarget.7755","volume":"7","author":"T Kato","year":"2016","unstructured":"Kato, T. et al. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. Oncotarget. 7, 17652\u201317664 (2016).","journal-title":"Oncotarget."},{"key":"249_CR24","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708274","volume":"10","author":"S Jurmeister","year":"2018","unstructured":"Jurmeister, S. et al. Identification of potential therapeutic targets in prostate cancer through a cross-species approach. EMBO Mol. Med. 10, e8274 (2018).","journal-title":"EMBO Mol. Med."},{"key":"249_CR25","unstructured":"U.S. National Institutes of Health - ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov (2019)."},{"key":"249_CR26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3324\/haematol.2010.037408","volume":"96","author":"T Cardesa-Salzmann","year":"2011","unstructured":"Cardesa-Salzmann, T. et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica. 96, 996\u20131001 (2011).","journal-title":"Haematologica."},{"key":"249_CR27","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313\u20132323 (2008).","journal-title":"N. Engl. J. Med."},{"key":"249_CR28","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1200\/JCO.2014.57.7080","volume":"33","author":"K Dybkaer","year":"2015","unstructured":"Dybkaer, K. et al. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J. Clin. Oncol. 33, 1379\u20131388 (2015).","journal-title":"J. Clin. Oncol."},{"key":"249_CR29","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","volume":"70","author":"V Fernandez","year":"2010","unstructured":"Fernandez, V. et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 70, 1408\u20131418 (2010).","journal-title":"Cancer Res."},{"key":"249_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483, 603\u2013607 (2012).","journal-title":"Nature."},{"key":"249_CR31","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/bioinformatics\/btq431","volume":"26","author":"B Carvalho","year":"2010","unstructured":"Carvalho, B. & Irizarry, R. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 26, 2363\u20132367 (2010).","journal-title":"Bioinformatics."},{"key":"249_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier, L., Cope, L., Bolstad, B. & Irizarry, R. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20, 307\u2013315 (2004).","journal-title":"Bioinformatics."},{"key":"249_CR33","doi-asserted-by":"publisher","first-page":"19079","DOI":"10.18632\/oncotarget.24901","volume":"9","author":"V Szablewski","year":"2018","unstructured":"Szablewski, V. et al. An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy. Oncotarget. 9, 19079\u201319099 (2018).","journal-title":"Oncotarget."},{"key":"249_CR34","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood-2009-07-232801","volume":"115","author":"E De Bruyne","year":"2010","unstructured":"De Bruyne, E. et al. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood. 115, 2430\u20132440 (2010).","journal-title":"Blood."},{"key":"249_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-15-0163","volume":"4","author":"S Van Lint","year":"2016","unstructured":"Van Lint, S. et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol. Res. 4, 146\u2013156 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"249_CR36","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares, P., Colomer, D. & Campo, E. Molecular pathogenesis of mantle cell lymphoma. J. Clin. Invest. 122, 3416\u20133423 (2012).","journal-title":"J. Clin. Invest."},{"key":"249_CR37","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.24797","volume":"92","author":"JM Vose","year":"2017","unstructured":"Vose, J. M. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am. J. Hematol. 92, 806\u2013813 (2017).","journal-title":"Am. J. Hematol."},{"key":"249_CR38","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20150194","volume":"35","author":"L Beke","year":"2015","unstructured":"Beke, L. et al. MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells. Biosci. Rep. 35, e00267 (2015).","journal-title":"Biosci. Rep."},{"key":"249_CR39","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1021\/acs.jmedchem.6b00052","volume":"59","author":"B Tour\u00e9","year":"2016","unstructured":"Tour\u00e9, B. et al. Toward the validation of maternal embryonic leucine zipper kinase: discovery, optimization of highly potent and selective inhibitors, and preliminary biology insight. J. Med. Chem. 59, 4711\u20134723 (2016).","journal-title":"J. Med. Chem."},{"key":"249_CR40","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1016\/j.bmc.2017.03.018","volume":"25","author":"R Edupuganti","year":"2017","unstructured":"Edupuganti, R. et al. Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth. Bioorg. Med. Chem. 25, 2609\u20132616 (2017).","journal-title":"Bioorg. Med. Chem."},{"key":"249_CR41","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.18632\/oncotarget.790","volume":"3","author":"S Chung","year":"2012","unstructured":"Chung, S. et al. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 3, 1629\u20131640 (2012).","journal-title":"Oncotarget."},{"key":"249_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbrc.2014.03.034","volume":"447","author":"Y Cho","year":"2014","unstructured":"Cho, Y., Kang, Y., Kim, K., Cha, Y. & Cho, H. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor. Biochem. Biophys. Res. Commun. 447, 7\u201311 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"249_CR43","doi-asserted-by":"crossref","first-page":"57938","DOI":"10.18632\/oncotarget.18488","volume":"8","author":"T Matsuda","year":"2017","unstructured":"Matsuda, T. et al. p53-independent p21 induction by MELK inibition. Oncotarget. 8, 57938\u201357947 (2017).","journal-title":"Oncotarget."},{"key":"249_CR44","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.stemcr.2014.12.006","volume":"4","author":"S Kim","year":"2015","unstructured":"Kim, S. et al. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK\/FOXM1-dependent manner. Stem Cell Reports. 4, 226\u2013238 (2015).","journal-title":"Stem Cell Reports."},{"key":"249_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/iep.12307","volume":"100","author":"Y Feng","year":"2019","unstructured":"Feng, Y. et al. Investigation of expressions of PDK1, PLK1 and c-MYC in diffuse large B-cell lymphoma. Int. J. Exp. Pathol. 100, 32\u201340 (2019).","journal-title":"Int. J. Exp. Pathol."},{"key":"249_CR46","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3324\/haematol.2011.053421","volume":"97","author":"S Uddin","year":"2012","unstructured":"Uddin, S. et al. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica. 97, 1092\u20131100 (2012).","journal-title":"Haematologica."},{"key":"249_CR47","first-page":"1469","volume":"130","author":"H Guo","year":"2017","unstructured":"Guo, H. et al. FoxM1: a new therapeutic target for Mantle cell lymphoma. Blood. 130, 1469 (2017).","journal-title":"Blood."},{"key":"249_CR48","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.7150\/jca.29807","volume":"10","author":"Y Deng","year":"2019","unstructured":"Deng, Y. et al. EZH2\/Bcl-2 coexpression predicts worse survival in diffuse large B-cell lymphomas and demonstrates poor efficacy to rituximab in localized lesions. J Cancer. 10, 2006\u20132017 (2019).","journal-title":"J Cancer."},{"key":"249_CR49","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"Z Xu-Monette","year":"2012","unstructured":"Xu-Monette, Z. et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 120, 3986\u20133996 (2012).","journal-title":"Blood."},{"key":"249_CR50","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1080\/1042819021000032917","volume":"43","author":"R Amini","year":"2002","unstructured":"Amini, R. et al. A novel B-cell line (U-2932) estabilshed from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma. 43, 2179\u20132189 (2002).","journal-title":"Leuk Lymphoma."},{"key":"249_CR51","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","volume":"127","author":"H Amin","year":"2003","unstructured":"Amin, H. et al. Characterization of 4 mantle cell lymphoma cell lines. Arch. Pathol. Lab. Med. 127, 424\u2013431 (2003).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"249_CR52","volume":"6","author":"A Stefka","year":"2016","unstructured":"Stefka, A. et al. Anti-myeloma activity of MELK inhibitor OTS167:effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells. Blood. Cancer J. 6, e460 (2016).","journal-title":"Cancer J."},{"key":"249_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10565-018-9435-z","volume":"35","author":"E Okur","year":"2019","unstructured":"Okur, E. & Yerlikaya, A. A novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis. Cell Biol. Toxicol. 35, 33\u201347 (2019).","journal-title":"Cell Biol. Toxicol."},{"key":"249_CR54","doi-asserted-by":"publisher","unstructured":"Adams, C., Clark-Garvey, S., Porcu, P. & Eischen, C. Targeting the Bcl-2 family in B cell lymphoma. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2018.00636 (2019).","DOI":"10.3389\/fonc.2018.00636"},{"key":"249_CR55","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","volume":"133","author":"A Zelenetz","year":"2019","unstructured":"Zelenetz, A. et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 133, 1964\u20131976 (2019).","journal-title":"Blood."},{"key":"249_CR56","doi-asserted-by":"publisher","first-page":"27946","DOI":"10.18632\/oncotarget.8547","volume":"7","author":"L Bate-Eya","year":"2016","unstructured":"Bate-Eya, L. et al. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget. 7, 27946\u201327958 (2016).","journal-title":"Oncotarget."},{"key":"249_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-019-0133-1","author":"S Jilg","year":"2019","unstructured":"Jilg, S. et al. Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. Exp. Hematol. Oncol. https:\/\/doi.org\/10.1186\/s40164-019-0133-1 (2019).","journal-title":"Exp. Hematol. Oncol."},{"key":"249_CR58","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"A Roberts","year":"2016","unstructured":"Roberts, A. et al. Targeting BCL2 with VEnetoclax in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 374, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0249-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0249-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0249-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:15:18Z","timestamp":1671207318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0249-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,18]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0249-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,18]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"87"}}